Poland· PL-100074343

Zincteral

A zinc sulfate product containing zinci sulfas, registered in Poland by Teva Pharmaceuticals Polska Sp. z o.o.. The same ATC class is registered in 3 of our 19 countries.

ATC A12CB01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedZincteralATCA12CB01REGISTER NO.PL-100074343PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Zinc sulfate is registered in 3 of 19 countries.

Countries holding a registration under ATC A12CB01 (zinc sulfate), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Zinc sulfate · ATC A12CB01

3 / 19 countries

  • Finlandprice
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Zinci sulfas
Manufacturer
Teva Pharmaceuticals Polska Sp. z o.o.
Country
Poland (PL)
ATC code
A12CB01
ATC class
Zinc sulfate
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990221813
  • gtin
    05909990221820

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

128 interactions on record for zinc sulfate.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Zinc sulfate · interactions on record

128 records

  • 6 severe
  • 31 moderate
  • 91 minor

Most severe, free to view

  • RaltegravirJ05AJ01severe
  • ElvitegravirJ05AJ02severe
  • DolutegravirJ05AJ03severe
  • RaltegravirJ05AX08severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Zinc sulfate in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zinc sulfate products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Zinc Sulfate
  • Norway · Solvezink
  • Sweden · Solvezink

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b5969abe-03c9-4f8b-ae39-8f48440cebc7
GET /v1/drugs/b5969abe-03c9-4f8b-ae39-8f48440cebc7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "45 mg Zn2+",
  "packaging": "05909990221813 ¦ Rp ¦ 11199\n50 tabl.\n05909990221820 ¦ Rp ¦ 11200\n150 tabl.",
  "substance": "Zinci sulphas 124 mg",
  "common_name": "Zinci sulfas",
  "pl_product_id": "100074343",
  "pozwolenie_nr": "02218",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about zinc sulfate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.